News Update - Action Alert

Sign-On Extended!

PPMD and a coalition of Duchenne foundations continue to work together on preparing for the Sarepta Ad Comm. As of today, we are still waiting on a new confirmed date. With the postponement of the Ad Comm, the Congressional letter to FDA remains open. Has your House Members signed on yet?
January 25, 2016 | Urge your Representative to take action 

FDA Ad Comm for Eteplirsen Postponed Due to Inclement Weather

We are deeply saddened, disappointed, and distressed to report that the highly-anticipated Ad Comm for eteplirsen has been postponed due to the blizzard anticipated to hit DC on Friday. We are grateful to our extraordinarily powerful Duchenne community who has been willing to travel into the eye of this storm to fight Duchenne. Our community has proven once again to be a force stronger than any winter storm, and much stronger than Duchenne itself. As soon as we receive any updates regarding a new date for the Ad Comm, we will let you know.
January 20, 2016 | Learn more 

News Update

Webinar Recording: HOPE-Duchenne Trial - Capricor Therapeutics

Last week, PPMD, Coalition Duchenne, and Capricor hosted a webinar to discuss the HOPE-Duchenne trial which recently opened for enrollment.
January 19, 2016 | Learn more 

News Update

Marathon Expanded Access Program for Deflazacort

There have been questions about whether taking Marathon’s deflazacort would impact involvement in currently ongoing and/or future clinical trials. We have had the opportunity to talk both with Marathon Pharmaceuticals, as well as several other industry partners, about the use of Marathon’s deflazacort.
January 18, 2016 | Learn more 

News Update - Action Alert

Urge House Member - Apply FDASIA Tools to Duchenne

There has never been a moment like this in our Duchenne community. Today the FDA released briefing documents on the application for eteplirsen. It is clear that we continue to face a serious regulatory challenge as a community.
January 15, 2016 | Urge your Representative to take action 

News Update - eNews

End Duchenne eNews: New Year, New Hope

Catch up on the latest research and community updates in this month's End Duchenne eNews.
January 15, 2016 | Learn more 

A Blow to Our Community – But Our Work Continues

Today our community was dealt a painful blow as the FDA issued a Complete Response letter to BioMarin regarding the company’s New Drug Application (NDA) for Kyndrisa (drisapersen). As stated in BioMarin’s press release, “The FDA issues Complete Response letters to indicate that the review cycle for an application is complete and that the application is not ready for approval in its present form. FDA has concluded that the standard of substantial evidence of effectiveness has not been met.”
January 14, 2016 | Learn more 

News Update

PPMD Responds to Revisions to “The Common Rule”

The Common Rule or the 'Federal Policy for the Protection of Human Subjects' is the policy that determines how you are consented when participating in trials and research, what types of research are considered to be ethical, and how biomedical samples acquired from patients can be used and stored.
January 13, 2016 | Learn more 

News Update

Dysphagia in Duchenne: practical recommendations to guide management

Dysphasia, or difficulty swallowing, effects many patients with Duchenne. Complaints of "something stuck in my throat" are not uncommon. A new article on dysphagia in Duchenne presents a clear step by step plan of care.
January 8, 2016 | Learn more 

News Update

Webinar 1/13/16: HOPE-Duchenne Trial - Capricor Therapeutics

Please join PPMD and Capricor as we host a webinar Wednesday, January 13 at 1pm eastern to discuss the HOPE-Duchenne trial which recently opened for enrollment in the US.
January 7, 2016 | Learn more 

News Update

We did it! Over $270,000 raised to support early-stage research.

Last month PPMD told you we hoped to raise $200,000 to support new, early-stage research. And how did you respond? By not only hitting our goal, but surpassing it! 
January 5, 2016 | Learn more 

News Update

Finding Hope in CRISPR/Cas9

Duchenne made national headlines over the holidays thanks to the latest news on gene editing technology. PPMD wanted to help take a deeper dive into gene editing and CRISPR/Cas9 so that we can better understand the potential of this cutting-edge technology.
January 4, 2016 | Learn more 

News Update

Last chance to have your donation doubled!

Just a few hours left to match every single gift! We’re so close to hitting our goal—but we need to raise $24,000 more by midnight tonight. Help us take full advantage of the matching gift by making a tax-deductible donation before midnight!
December 31, 2015 | Learn more 

 
Connect with PPMD
Facebook YouTube Twitter

Quick Links
How We Help



Our family-centered approach is at the heart of everything we do. Learn more.

Quick Links

Fund Research

More Links

PPMD Sites

new amazon banner